Efficacy and Safety of Conversion Therapy by Intraperitoneal and Intravenous Paclitaxel Plus Oral S-1 in Gastric Cancer Patients With Peritoneal Metastasis: A Prospective Phase II Study

Frontiers in Oncology

Wen-Tao Liu¹  Zhen-Qiang Wang¹  Ya-Nan Zheng¹  Xue-Xin Yao¹  Zheng-Lun Zhu¹  Chang-Yu He¹  Chao Yan¹  Wei Xu¹  Zheng-Gang Zhu¹  Chen Li¹  Zhen-Tian Ni¹  Min Yan¹  Zhong-Yin Yang¹  Sheng Lu¹  Min Shi²  Jun Zhang²  Jun-Wei Wu²  Wen-Qi Xi²  Fei Yuan³  Huan Zhang⁴ 

[1] Department of General Surgery, Gastrointestinal Surgery, Shanghai Key laboratory of Gastric Neoplasms, Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China;Department of Oncology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China;Department of Pathology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China;Department of Radiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China;

关键词: gastric cancer;    peritoneal metastasis;    intraperitoneal chemotherapy;    paclitaxel;    conversion surgery;   

DOI  :  10.3389/fonc.2022.905922

来源: DOAJ

【 摘 要 】

BackgroundNeoadjuvant intraperitoneal and systemic chemotherapy (NIPS) has shown promising results in gastric cancer (GC) with peritoneal metastasis. However, clinical practice experience of NIPS is still lacking in China. In this study, we investigate the efficacy and safety of NIPS in Chinese patients.MethodsEligible patients received NIPS every 3 weeks. Gastrectomy was performed for patients who met the criteria of conversion surgery. The primary end point was 1-year overall survival (OS) rate. Secondary end points were the response rate, toxic effects, conversion surgery outcomes and median survival time (MST).ResultsSixty-seven patients were enrolled. The primary endpoint was achieved with 1-year OS rate reached 67.2% (95% CI, 56.8%-79.4%). Conversion surgery was performed in 42 patients (62.9%), and R0 resection was achieved in 23 patients (54.8%) with the MST of 31.3 months (95% CI, 24.3-38.3). And the MST was 19.3 months (95% CI, 16.4-22.2) for all patients. Toxicity and surgical complications were well-tolerated. Moreover, sex, R0 resection, pathological nodal stage and tumor regression grade (TRG) were independent prognostic factors for patients who underwent conversion surgery.ConclusionThe NIPS is effective and safe in treating GC patients with peritoneal metastasis. Male patients, patients who underwent R0 resection, patients with ypN0-1 or TRG 1 after conversion surgery are more likely to benefit from the NIPS.Clinical Trial Registrationhttp://www.chictr.org.cn/, identifier https://clinicaltrials.gov/ ().

【 授权许可】

Unknown